Showing results (11-20 of 72) with videos related to
Sort By:
Pageof 8
Rheumatology and Therapy|May 16, 2019
Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic DrugsAlvin F Wells, Janie Parrino, Erin K Mangan, et al.Rheumatology (Oxford, England)|December 28, 2018
Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritisPaul Emery, Juan Rondon, Janie Parrino, et al.Arthritis Research & Therapy|April 9, 2020
Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomesCem Gabay, Gerd R Burmester, Vibeke Strand, et al.The Journal of Allergy and Clinical Immunology|January 23, 2018
Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthmaSteven F Weinstein, Rohit Katial, Shyamalie Jayawardena, et al.Journal of Clinical Epidemiology|March 17, 2004
Disease progression in HIV-infected patients treated with stavudine vs. zidovudineAmy C Justice, Daniel S Stein, Gregory P Fusco, et al.Journal of the American Academy of Dermatology|June 9, 2016
Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)Eric L Simpson, Abhijit Gadkari, Margitta Worm, et al.Arthritis Research & Therapy|September 8, 2016
Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trialVibeke Strand, Mark Kosinski, Chieh-I Chen, et al.Annals of the Rheumatic Diseases|November 19, 2016
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trialGerd R Burmester, Yong Lin, Rahul Patel, et al.Arthritis & Rheumatology (Hoboken, N.J.)|November 19, 2016
Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor InhibitorsRoy Fleischmann, Janet van Adelsberg, Yong Lin, et al.Allergology International : Official Journal of the Japanese Society of Allergology|May 24, 2020
Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST studyYuji Tohda, Yoichi Nakamura, Takao Fujisawa, et al.Pageof 8